Efficacy and Safety of Anlotinib-Based Regimens in Metastatic Breast Cancer: A Multicenter Real-World Study
{{output}}
Background: Anlotinib, a multi-target small-molecule receptor tyrosine kinase inhibitor, can inhibit tumor angiogenesis proliferation and remains underexplored in metastatic breast cancer (MBC). Therefore, we aimed to analyze the... ...
